Ardena at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

Ardena brings 2 presentations to EBF 2026 in Barcelona. Its program covers qualifying versus validating vaccine ligand-binding assays for clinical samples. It also addresses LC–MS quantification of sphingolipids as biomarkers in lysosomal and neurodegenerative disorders.

Organization	EBF 2026 Attendance
Ardena Ghent, Belgium	◇Sponsor
ardena.com Bioanalytical CROsSponsor Drug development CDMO and CRO offering formulation, manufacturing and regulated bioanalysis services.	Talk Tue Nov 17 11:50am–12:10pm Part of Session 3: Vaccines Vaccine Ligand-Binding Assays for Clinical Sample Analysis: Qualification vs. Validation - A Fit-for-Purpose Approach to Dilution Series and Cut-Point Selection Vaccines · Ligand binding Talk Wed Nov 18 12–12:20pm Part of Session 13: BioA Clinic Analytical Challenges in Sphingolipid Quantification: Enabling Biomarker Discovery in Lysosomal and Neurodegenerative Disorders Biomarkers · LC–MS

Organization

EBF 2026 Attendance

Ardena

Ghent, Belgium

ardena.com

Bioanalytical CROsSponsor

Drug development CDMO and CRO offering formulation, manufacturing and regulated bioanalysis services.

Talk

Tue Nov 17
11:50am–12:10pm

Part of Session 3: Vaccines

Vaccine Ligand-Binding Assays for Clinical Sample Analysis: Qualification vs. Validation - A Fit-for-Purpose Approach to Dilution Series and Cut-Point Selection

Vaccines · Ligand binding